Free Trial

Ventyx Biosciences (VTYX) Stock Forecast & Price Target

$2.84
+0.28 (+10.94%)
(As of 07/15/2024 ET)

Ventyx Biosciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$15.75
454.58% Upside
High Forecast$62.00
Average Forecast$15.75
Low Forecast$5.00
TypeCurrent Forecast
7/17/23 to 7/16/24
1 Month Ago
6/17/23 to 6/16/24
3 Months Ago
4/18/23 to 4/17/24
1 Year Ago
7/17/22 to 7/17/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
8 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$15.75$15.75$21.75$57.67
Forecasted Upside454.58% Upside62.77% Upside75.35% Upside63.71% Upside
Get Ventyx Biosciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for VTYX and its competitors with MarketBeat's FREE daily newsletter.

VTYX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

VTYX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Ventyx Biosciences Stock vs. The Competition

TypeVentyx BiosciencesMedical CompaniesS&P 500
Consensus Rating Score
2.56
2.71
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside454.58% Upside996.86% Upside9.40% Upside
News Sentiment RatingVery Positive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/13/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral$6.00 ➝ $6.00+101.34%
6/6/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$12.00 ➝ $10.00+125.22%
3/13/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$16.00 ➝ $15.00+87.97%
3/12/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight$7.00 ➝ $16.00+99.00%
2/28/2024Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Slutsky
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
11/10/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ In-Line$43.00 ➝ $5.00+113.67%
11/7/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight$46.00 ➝ $6.00+124.72%
11/7/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$6.00-57.42%
8/11/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$63.00 ➝ $62.00+77.80%
5/12/2023500.com
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingReiterates
12/19/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$50.00+53.19%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 03:04 AM ET.

VTYX Forecast - Frequently Asked Questions

What is Ventyx Biosciences' forecast for 2024?

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Ventyx Biosciences is $15.75, with a high forecast of $62.00 and a low forecast of $5.00.

Should I buy or sell Ventyx Biosciences stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ventyx Biosciences in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VTYX shares.

Does Ventyx Biosciences's stock price have much upside?

According to analysts, Ventyx Biosciences's stock has a predicted upside of 62.77% based on their 12-month stock forecasts.

What analysts cover Ventyx Biosciences?

Ventyx Biosciences has been rated by research analysts at HC Wainwright, and Oppenheimer in the past 90 days.

Do Wall Street analysts like Ventyx Biosciences more than its competitors?

Analysts like Ventyx Biosciences less than other "medical" companies. The consensus rating score for Ventyx Biosciences is 2.56 while the average consensus rating score for "medical" companies is 2.71. Learn more on how VTYX compares to other companies.


This page (NASDAQ:VTYX) was last updated on 7/16/2024 by MarketBeat.com Staff

From Our Partners